IL131857A - food suplament - Google Patents
food suplamentInfo
- Publication number
- IL131857A IL131857A IL13185798A IL13185798A IL131857A IL 131857 A IL131857 A IL 131857A IL 13185798 A IL13185798 A IL 13185798A IL 13185798 A IL13185798 A IL 13185798A IL 131857 A IL131857 A IL 131857A
- Authority
- IL
- Israel
- Prior art keywords
- carnitine
- nutritional supplement
- acetyl
- weight
- propionyl
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 36
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims abstract description 35
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 229950007002 phosphocreatine Drugs 0.000 claims abstract description 7
- 229960003624 creatine Drugs 0.000 claims abstract description 6
- 239000006046 creatine Substances 0.000 claims abstract description 6
- 208000016254 weariness Diseases 0.000 claims abstract description 4
- 230000006978 adaptation Effects 0.000 claims abstract description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 61
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- -1 isovaleryl Chemical group 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 239000002526 disodium citrate Substances 0.000 claims description 3
- 235000019262 disodium citrate Nutrition 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043046 isoleucine 50 mg Drugs 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 8
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 34
- 238000011282 treatment Methods 0.000 description 25
- 239000000902 placebo Substances 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 12
- 125000002252 acyl group Chemical group 0.000 description 10
- 229960004203 carnitine Drugs 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 7
- 206010003549 asthenia Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 3
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 3
- 206010058892 Carnitine deficiency Diseases 0.000 description 3
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000015606 cardiovascular system disease Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 208000013363 skeletal muscle disease Diseases 0.000 description 3
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 108010076625 carnitine octanoyltransferase Proteins 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000029372 muscular lipidosis Diseases 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000011667 skeletal muscle adaptation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021476 total parenteral nutrition Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/80—Geriatric
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/806—Salt or mineral substitute
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000185A IT1291127B1 (it) | 1997-04-01 | 1997-04-01 | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| PCT/IT1998/000069 WO1998043499A2 (en) | 1997-04-01 | 1998-03-27 | Nutritional supplement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL131857A0 IL131857A0 (en) | 2001-03-19 |
| IL131857A true IL131857A (en) | 2002-04-21 |
Family
ID=11404926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13185798A IL131857A (en) | 1997-04-01 | 1998-03-27 | food suplament |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6245378B1 (it) |
| EP (1) | EP0973415B1 (it) |
| JP (1) | JP2001517085A (it) |
| KR (1) | KR20010005865A (it) |
| CN (1) | CN1074912C (it) |
| AT (1) | ATE202675T1 (it) |
| AU (1) | AU729412B2 (it) |
| BR (1) | BR9807905A (it) |
| CA (1) | CA2285332C (it) |
| DE (1) | DE69801047T2 (it) |
| DK (1) | DK0973415T3 (it) |
| ES (1) | ES2159179T3 (it) |
| GR (1) | GR3036777T3 (it) |
| HK (1) | HK1026124A1 (it) |
| IL (1) | IL131857A (it) |
| IT (1) | IT1291127B1 (it) |
| PT (1) | PT973415E (it) |
| SK (1) | SK282907B6 (it) |
| WO (1) | WO1998043499A2 (it) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2146555B1 (es) * | 1999-01-22 | 2001-03-01 | Helsint S A L | Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico. |
| IT1306173B1 (it) * | 1999-07-23 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare. |
| IT1306179B1 (it) | 1999-07-28 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale. |
| AU1800801A (en) * | 1999-11-17 | 2001-05-30 | Eric H. Kuhrts | Exercise and muscle enhancement formulations |
| US6429230B1 (en) * | 2000-01-19 | 2002-08-06 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| US6914076B2 (en) * | 2000-01-19 | 2005-07-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| US6335369B1 (en) * | 2000-01-19 | 2002-01-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| IT1316998B1 (it) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. |
| US8252309B2 (en) * | 2000-04-04 | 2012-08-28 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Dietary supplement energy-providing to skeletal muscles |
| IT1317043B1 (it) | 2000-06-14 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio. |
| AU9093901A (en) * | 2000-09-14 | 2002-03-26 | Univ Nebraska | Creatine ester pronutrient compounds and formulations |
| US20030212136A1 (en) | 2001-09-14 | 2003-11-13 | Vennerstrom Jonathan L. | Creatine ester pronutrient compounds and formulations |
| US20020150627A1 (en) * | 2001-01-26 | 2002-10-17 | Stout Jeffrey Ray | Composition containing creatine and phosphorus |
| DE10133200A1 (de) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Carnitin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
| US6652891B2 (en) | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
| ITRM20020194A1 (it) | 2002-04-09 | 2003-10-09 | Sigma Tau Healthscience Spa | Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo. |
| ITRM20020620A1 (it) * | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
| US7776913B2 (en) * | 2002-12-13 | 2010-08-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Carnitines for treating or preventing disorders caused by andropause |
| US7288570B2 (en) * | 2002-12-20 | 2007-10-30 | Nutricia N.V. | Stimulation of in vivo production of proteins |
| DE20321010U1 (de) * | 2003-03-28 | 2005-12-29 | Schymura, Martin | Fruchtgummizusammensetzung |
| JP2006137746A (ja) * | 2004-10-13 | 2006-06-01 | Otsuka Pharmaceut Factory Inc | オレキシン誘導組成物 |
| EP1871883A1 (en) * | 2005-03-02 | 2008-01-02 | Metanomics GmbH | Process for the production of fine chemicals |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| US20070248648A1 (en) * | 2006-04-20 | 2007-10-25 | Next Proteins, Inc. | High protein, fatigue reducing powder |
| US10426750B1 (en) | 2007-09-18 | 2019-10-01 | Thermolife International, Llc | Amino acid supplement formulations |
| US10646508B1 (en) | 2007-09-18 | 2020-05-12 | Thermolife International, Llc | Method of safely administering nitrate dietary supplements and compositions |
| US10435356B1 (en) | 2007-09-18 | 2019-10-08 | Thermolife International, Llc | Amino acid compositions |
| US8466187B2 (en) | 2007-09-18 | 2013-06-18 | Thermolife International, Llc | Amino acid compositions |
| US10426792B1 (en) * | 2007-09-18 | 2019-10-01 | Thermolife International, Llc | Amino acid compositions |
| CN101524155B (zh) * | 2009-04-20 | 2012-10-10 | 北京康比特体育科技股份有限公司 | 一种氨基酸组合物 |
| JP2014532032A (ja) * | 2011-04-05 | 2014-12-04 | ロンザ・リミテッド | 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのｌ−カルニチン、その塩および誘導体の使用 |
| EP2508179A1 (en) * | 2011-04-05 | 2012-10-10 | Lonza Ltd. | Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function |
| AU2012242565B2 (en) | 2011-04-13 | 2017-05-11 | Thermolife International, Llc | N-Acetyl Beta Alanine methods of use |
| CN102512655B (zh) * | 2011-11-30 | 2013-10-30 | 北京康比特体育科技股份有限公司 | 左旋肉碱组合物和制剂，及其制备方法和应用 |
| WO2014045065A2 (en) * | 2012-09-22 | 2014-03-27 | Bslim Holdings Limited | Dietary compositions and their uses |
| CN103271350B (zh) * | 2013-03-04 | 2014-09-24 | 中国航天员科研训练中心 | 空间站航天员太空高能压缩食品及其制法 |
| GB201304112D0 (en) * | 2013-03-07 | 2013-04-24 | Univ Nottingham | Modulation of energy expenditure |
| CN104415043B (zh) * | 2013-09-03 | 2017-03-15 | 上海华拓医药科技发展有限公司 | 一种磷酸肌酸二钠盐在制备抗癌因性疲乏药物中的用途 |
| BR112016028654A2 (pt) * | 2014-06-12 | 2018-07-10 | Lonza Ag | método para diminuição de dano muscular esquelético e / ou estresse oxidativo em mamíferos |
| WO2017075289A1 (en) | 2015-10-27 | 2017-05-04 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
| US10674746B2 (en) | 2015-10-27 | 2020-06-09 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
| CA3008033A1 (en) * | 2015-12-18 | 2017-06-22 | Lonza, Inc. | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals |
| AU2019357838A1 (en) * | 2018-10-10 | 2021-04-15 | So Ngor Sally LEUNG | Health product composition for supplementing deficiency, preparation method therefor and application thereof |
| US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
| US20220313644A1 (en) * | 2021-04-06 | 2022-10-06 | Celagenex Research (India) Pvt. Ltd. | Synergistic composition for potentiating stabilized atp |
| CN118638020A (zh) * | 2024-08-08 | 2024-09-13 | 杭州海尔希畜牧科技有限公司 | L-天门冬氨酸l(-)肉碱(1:1)的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400371A (en) * | 1972-11-06 | 1983-08-23 | Biocarn Ltd. | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats |
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
| AU518617B2 (en) * | 1977-04-29 | 1981-10-08 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutic application of acetyl-d, 1-carnitine |
| DE2903558C2 (de) * | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Verwendung von L-Carnitin |
| IT1156769B (it) * | 1978-05-25 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di altri acil derivati della carnitina |
| US4346107A (en) | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| IT1119853B (it) * | 1979-09-21 | 1986-03-10 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie |
| IT1119854B (it) * | 1979-09-21 | 1986-03-10 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente l-carnitina per il trattamento di disfunzioni cardiache |
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| IT1142934B (it) * | 1981-11-06 | 1986-10-15 | Sigma Tau Ind Farmaceuti | Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene |
| IT1157238B (it) * | 1982-10-29 | 1987-02-11 | Sigma Tau Ind Farmaceuti | Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile |
| CH655005A5 (it) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
| DE3463261D1 (en) * | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
| DE3420828A1 (de) * | 1984-06-05 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Fungizide mittel |
| US4604286A (en) * | 1984-09-17 | 1986-08-05 | Daigo Nutritive Chemicals, Ltd. | Infusion solution for parenteral nutrition |
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| ATE88631T1 (de) * | 1986-09-17 | 1993-05-15 | Clintec Nutrition Co | Zusatznahrung bzw. therapie fuer personen mit risiko oder in behandlung fuer arteriosklerotische vaskulaere, kardiovaskulaere und/oder thrombotische erkrankungen. |
| IT1245699B (it) * | 1991-05-29 | 1994-10-14 | Sigma Tau Ind Farmaceuti | Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi |
| IT1258491B (it) * | 1992-09-24 | 1996-02-26 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi. |
| US5817329A (en) * | 1997-02-28 | 1998-10-06 | Gardiner; Paul T. | Nutritional supplement for increased muscle size and strength for body builders |
-
1997
- 1997-04-01 IT IT97RM000185A patent/IT1291127B1/it active IP Right Grant
-
1998
- 1998-03-27 IL IL13185798A patent/IL131857A/en not_active IP Right Cessation
- 1998-03-27 ES ES98912704T patent/ES2159179T3/es not_active Expired - Lifetime
- 1998-03-27 SK SK1349-99A patent/SK282907B6/sk unknown
- 1998-03-27 CN CN98803848A patent/CN1074912C/zh not_active Expired - Fee Related
- 1998-03-27 BR BR9807905-0A patent/BR9807905A/pt not_active IP Right Cessation
- 1998-03-27 DK DK98912704T patent/DK0973415T3/da active
- 1998-03-27 WO PCT/IT1998/000069 patent/WO1998043499A2/en not_active Application Discontinuation
- 1998-03-27 EP EP98912704A patent/EP0973415B1/en not_active Expired - Lifetime
- 1998-03-27 CA CA002285332A patent/CA2285332C/en not_active Expired - Lifetime
- 1998-03-27 KR KR1019997008941A patent/KR20010005865A/ko not_active Application Discontinuation
- 1998-03-27 JP JP54137898A patent/JP2001517085A/ja active Pending
- 1998-03-27 AT AT98912704T patent/ATE202675T1/de active
- 1998-03-27 PT PT98912704T patent/PT973415E/pt unknown
- 1998-03-27 DE DE69801047T patent/DE69801047T2/de not_active Expired - Lifetime
- 1998-03-27 US US09/147,179 patent/US6245378B1/en not_active Expired - Lifetime
- 1998-03-27 AU AU67462/98A patent/AU729412B2/en not_active Expired
-
2000
- 2000-08-30 HK HK00105409A patent/HK1026124A1/xx not_active IP Right Cessation
-
2001
- 2001-10-03 GR GR20010401638T patent/GR3036777T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998043499A3 (en) | 1999-01-07 |
| SK282907B6 (sk) | 2003-01-09 |
| HK1026124A1 (en) | 2000-12-08 |
| CN1251496A (zh) | 2000-04-26 |
| IT1291127B1 (it) | 1998-12-29 |
| GR3036777T3 (en) | 2002-01-31 |
| BR9807905A (pt) | 2000-02-22 |
| AU6746298A (en) | 1998-10-22 |
| DE69801047T2 (de) | 2001-10-31 |
| EP0973415A2 (en) | 2000-01-26 |
| WO1998043499A2 (en) | 1998-10-08 |
| CA2285332C (en) | 2007-11-27 |
| SK134999A3 (en) | 2000-05-16 |
| ES2159179T3 (es) | 2001-09-16 |
| DE69801047D1 (de) | 2001-08-09 |
| CA2285332A1 (en) | 1998-10-08 |
| ATE202675T1 (de) | 2001-07-15 |
| EP0973415B1 (en) | 2001-07-04 |
| US6245378B1 (en) | 2001-06-12 |
| ITRM970185A1 (it) | 1998-10-01 |
| IL131857A0 (en) | 2001-03-19 |
| PT973415E (pt) | 2001-10-30 |
| JP2001517085A (ja) | 2001-10-02 |
| DK0973415T3 (da) | 2001-09-24 |
| CN1074912C (zh) | 2001-11-21 |
| AU729412B2 (en) | 2001-02-01 |
| KR20010005865A (ko) | 2001-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2285332C (en) | Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals | |
| CA2334415C (en) | Compositions for increasing energy in vivo | |
| US5817329A (en) | Nutritional supplement for increased muscle size and strength for body builders | |
| Abraham et al. | Management of fibromyalgia: rationale for the use of magnesium and malic acid | |
| ES2655367T3 (es) | Bebida que comprende éster de hidroxibutirato y uso médico de la misma | |
| US6534480B2 (en) | Compositions for increasing energy in vivo | |
| TW200803761A (en) | Dietary supplement energy-providing to skeletal muscles | |
| AU750645B2 (en) | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH | |
| AU5253501A (en) | Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract | |
| Galloway et al. | Oral L-carnitine supplementation and exercise metabolism | |
| MXPA99008999A (en) | Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals | |
| US12128020B2 (en) | Administration of R-beta-hydroxybutyrate and related compounds in humans | |
| CZ347999A3 (cs) | Doplňková výživa pro snazší adaptaci kosterního svalstva vyčerpaného zatěžujícími výkony a paralyzování únavy asthenických jedinců | |
| US20220339142A1 (en) | Administration of r-beta-hydroxybutyrate salt blend and related compounds in humans | |
| US20240226043A1 (en) | Administration of r-beta-hydroxybutyrate and related compounds in humans | |
| US20220249419A1 (en) | C5 ketone compositions, and related methods, for therapeutic and performance supplementation | |
| EP1745789A1 (en) | Compositions comprising ribose for increasing energy in vivo | |
| SK12402002A3 (sk) | Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10 | |
| WO2023212319A1 (en) | Administration of r-beta-hydroxybutyrate salt blend and related compounds in humans | |
| Spragg | Does Carnitine Supplementation Enhance Exercise Performance in Healthy Adults? | |
| Mounteer | The use of ergogenic aids in athletes | |
| CZ20003831A3 (cs) | Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH | |
| Karlstad et al. | Enhanced Skeletal Muscle and Liver Protein Synthesis With Structured Lipid in Enterally Fed Burned Rats zyxwvutsrqponmlkjihgfedcbaZYXWVUTS | |
| EP0972516A1 (en) | Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |